Gabapentin Capsule
Product Images NDC 71610-188

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-188). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71610 0188 98

Gabapentin 300 mg oral capsules label by Aphena Pharma Solutions - Tennessee, LLC. The label shows NDC 71610-188-98, container size of 540 capsules, and manufacturer Aurobindo Pharma Limited, Hyderabad, India. It includes storage instructions and is marked for prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Formula (Gabapentin Fig1)

A text panel displaying an equation for calculating creatinine clearance (CLCr), which involves age, weight, serum creatinine, and an adjustment factor for female patients. The text is formatted as a scientific formula with variables and mathematical operations.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph comparing mean pain score over 8 weeks for placebo and gabapentin (3600 mg/day). The x-axis shows weeks from baseline to week 8, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain score ranging from 0 to 9. Gabapentin shows a decreasing trend in pain score, whereas placebo remains relatively stable.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting mean pain scores over a 7-week period for treatments with placebo and gabapentin at doses of 1800 mg/day and 2400 mg/day. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, showing pain score trends from baseline through week 7 for each treatment group.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders at Endpoint: Controlled PHN Studies' showing percentages of patients with ≥ 50% reduction in pain score in two studies. Study 1 compares PBO at 12% and GBP 3600 at 29%. Study 2 compares PBO at 14%, GBP 1800 at 32%, and GBP 2400 at 34%. Statistical significance indicated with ** for p < 0.01 and *** for p < 0.001.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Gabapentin Fig5)

A scatter plot chart depicting the percentage difference on the y-axis versus daily dose in milligrams on the x-axis, comparing results from three studies labeled as Study a, Study b, and Study c, with data points plotted for doses 600, 900, 1200, and 1800 mg.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure of Gabapentin showing its cyclohexane ring with attached amino and carboxyl groups, consistent with its generic composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.